RAS extended panel (KRAS, BRAF, NRAS, PIK3CA) Test in Chembur - Metropolis Healthcare
back-arrow-image Search Health Packages, Tests & More

RAS extended panel (KRAS, BRAF, NRAS, PIK3CA) Test

50+ booked in last 3 days

Test Overview

Identifying tumors that may respond to targeted therapies by assessing multiple gene targets simultaneously Identifying mutations that may help determine prognosis for patients with solid tumors.

Read More

Frequently Asked Questions

The assay detects KRAS, NRAS, BRAF and PIK3CA mutations from tissue to predict response to EGFR-targeted immunotherapy in metastatic colorectal cancer.

Yes, to predict response to EGFR-targeted immunotherapy in metastatic colorectal cancer.

Identifying tumors that may respond to targeted therapies by assessing multiple gene targets simultaneously Identifying mutations that may help determine prognosis for patients with solid tumors., Identifying specific mutations within genes known to be associated with response or resistance to specific cancer therapies.

Ratings & Reviews (0)

No reviews available

Why Metropolis?

Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.

We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.

lab image
115+ Advanced Labs
lab image
Trusted by Leading Doctors & Hospitals
lab images
Over 2000+ Scientific Officers
reports image
Proficiency Testing for Accurate Reports

Our Blog

Take a look at some of the related content from our blog